Comparison of medium-term survival outcomes between robot-assisted thoracoscopic surgery and video-assisted thoracoscopic surgery in treating primary lung cancer

Objectives Robot-assisted thoracoscopic surgery (RATS) for primary lung cancer has been spreading rapidly in Japan. While RATS has various technical advantages over video-assisted thoracoscopic surgery (VATS), the quality of surgery from an oncologic viewpoint must be maintained, and the evaluation...

Full description

Saved in:
Bibliographic Details
Published inGeneral thoracic and cardiovascular surgery Vol. 68; no. 9; pp. 984 - 992
Main Authors Haruki, Tomohiro, Kubouchi, Yasuaki, Takagi, Yuzo, Kidokoro, Yoshiteru, Matsui, Shinji, Nakanishi, Atsuyuki, Miwa, Ken, Taniguchi, Yuji, Nakamura, Hiroshige
Format Journal Article
LanguageEnglish
Published Singapore Springer Singapore 01.09.2020
Springer Nature B.V
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Objectives Robot-assisted thoracoscopic surgery (RATS) for primary lung cancer has been spreading rapidly in Japan. While RATS has various technical advantages over video-assisted thoracoscopic surgery (VATS), the quality of surgery from an oncologic viewpoint must be maintained, and the evaluation of medium- to long-term survival outcomes is momentous. Methods This study included 299 patients with primary lung cancer (VATS, n  = 246; RATS, n  = 53) who underwent lobectomy and mediastinal lymph node dissection at our hospital. We reviewed and compared perioperative factors, the number of dissected lymph nodes, and postoperative recurrence between the VATS and RATS groups. We also compared the postoperative survival rates among 98 patients (49 patients in each group) whose background factors were adjusted by propensity score matching (PSM). Results After PSM, a significant difference was found in the total operative time between the two groups ( p  < 0.01); however, no difference was found between the RATS console time and VATS total operative time ( p  = 0.68). Postoperative recurrence was not significantly different between the groups (VATS, 14%; RATS, 6%; p  = 0.18). The 3-year recurrence-free survival rate was not significantly different between the groups (VATS, 91.7%; RATS, 91.2%; p  = 0.21). Conclusions RATS had promising survival results, which were similar to those of VATS even after PSM. Further case series and longer observation periods are needed to determine what technical benefits of RATS may affect the prognosis of lung cancer.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1863-6705
1863-6713
DOI:10.1007/s11748-020-01312-7